CClinicalTrials.gg
CompletedNCT02086162RCTEDSSUpdated Nov 29, 2018Results posted

Randomized Controlled Trial (RCT) of a Motivational Decision Support System

An interventional study of Web-based motivational decision support system and NCI Education in Schizophrenia, sponsored by Dartmouth-Hitchcock Medical Center. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-11-29.

Sponsored by Dartmouth-Hitchcock Medical Center · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

In this study we will definitively test the decision support system in a randomized controlled trial (RCT) among smokers with severe mental illness (SMI) psychotic disorders. The Specific Aims of the study are:

  1. To determine whether use of the web-based decision support system leads to higher rates of initiation of smoking cessation treatment than use of a computerized educational pamphlet. We will also assess effectiveness on secondary outcomes, including smoking behavior, urges and outcome expectancies; level of dependence; intentions to quit and to use cessation treatment; and abstinence.
  2. To assess whether cognitive ability moderates initiation of smoking cessation treatment. Since cognitive impairment impedes use of standard web-based interventions by this group, and cognitive impairments likely supersede other potential moderators (education and socioeconomic status), this aim will be key to determining the success of our intervention and will guide further revisions if they are needed.
  3. To explore the effects of the decision support system and baseline cognitive ability on abstinence over 6 months

    1. We will examine the impact of the DSS on 7-day point prevalence tobacco abstinence at 6 months, and cumulative days of tobacco abstinence over 6 months.
    2. We will determine whether baseline cognition (scale scores) is associated with 7-day point prevalence tobacco abstinence at 6 months, and cumulative days of tobacco abstinence over 6 months.
Read the detailed description

Up to 80% of people with schizophrenia and schizoaffective disorders smoke - a rate that is four times the rate in the general population. Cessation treatments are effective, but these smokers don't use them. In order to provide an easy-to-use, cost-effective strategy to engage this group of smokers into effective treatments, we developed a single-session, web-based, motivational decision support system, Let's Talk About Smoking. The system incorporates features that insure high usability among those who can't use current websites due to cognitive impairments and low computer skills. It provides compelling content that engages users into evidence-based cessation treatments.

In this study we will definitively test the decision support system in a randomized controlled trial (RCT) among smokers with severe mental illness (SMI) psychotic disorders. Our proposed study design will enable us to test whether this system, designed for those with cognitive impairments, is effective among people with a range of cognitive abilities. The Specific Aims of the study are:

  1. To determine whether use of the web-based decision support system leads to higher rates of initiation of smoking cessation treatment than use of a computerized educational pamphlet. We will also assess effectiveness on secondary outcomes, including smoking behavior, urges and outcome expectancies; level of dependence; intentions to quit and to use cessation treatment; and abstinence.
  2. To assess whether cognitive ability moderates initiation of smoking cessation treatment. Since cognitive impairment impedes use of standard web-based interventions by this group, and cognitive impairments likely supersede other potential moderators (education and socioeconomic status), this aim will be key to determining the success of our intervention and will guide further revisions if they are needed.
  3. To explore the effects of the decision support system and baseline cognitive ability on abstinence over 6 months

    1. We will examine the impact of the DSS on 7-day point prevalence tobacco abstinence at 6 months, and cumulative days of tobacco abstinence over 6 months.
    2. We will determine whether baseline cognition (scale scores) is associated with 7-day point prevalence tobacco abstinence at 6 months, and cumulative days of tobacco abstinence over 6 months.
02

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Smoking
  • Tobacco
  • Motivation
  • Cessation Treatment
03

In context

Schizophrenia

3,471 studies on the registry are indexed under Schizophrenia; 472 are open to participants now.

This study's enrollment of 184 is above the median of 70 across 2,872 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

Dartmouth-Hitchcock Medical Center is the lead sponsor of 472 studies on the registry; 68 are open to participants now.

Of its 30 completed or terminated interventional studies of FDA-regulated products, 20 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 18-70 years old
  • DSM-IV-TR diagnosis psychotic disorder
  • in treatment at participating mental health center
  • current daily smoker
  • fluent in English
  • physically able to use computer
  • willing and able to give informed consent

Exclusion criteria

Exclusion Criteria:

  • past 2 weeks use of evidence based cessation treatment
  • psychiatric instability
  • current alcohol or drug dependence
  • pregnant or nursing
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
184 participants (actual)

Study arms

  • Experimental
    Behavioral intervention

    Web-based motivational decision support system

    Behavioral: Web-based motivational decision support system

  • Active comparator
    Educational intervention

    Computerized version of the National Cancer Institute (NCI) Educational Pamphlet

    Behavioral: NCI Education

Interventions

  • BehavioralWeb-based motivational decision support system
  • BehavioralNCI Education
06

What researchers measure

Primary outcomes

  1. Number of Subjects That Initiated Cessation Treatment

    Cessation treatment initiation and engagement will be collected from clinician attendance sheets in the medical record and medical record review for prescriptions. Medication use will be confirmed with self-report of taking medication.

    Time frame: 6 months

Secondary outcomes

  1. Number of Subjects With Confirmed Abstinence

    Biologically confirmed abstinence: we will confirm 7-day point prevalence abstinence at 6 month assessments (self-reported abstinence without any smoking, "not even a puff," for the past 7 days,) with expired carbon monoxide (reading ≤9).

    Time frame: 6 months

  2. Number of Subjects With a Quit Attempt With 7 or More Days of Self-reported Abstinence

    Time frame: 6 months

07

Results

Posted Oct 12, 2018

Participant flow

Participant flow — Overall Study
MilestoneLet's Talk About SmokingNational Cancer Institute (NCI) Computerized Education
Started7884
Completed6877
Not completed107
Withdrew: Withdrawal by subject44
Withdrew: Moved11
Withdrew: Lost to follow-up42
Withdrew: Death10

Outcome measures

PrimaryNumber of Subjects That Initiated Cessation Treatment

Cessation treatment initiation and engagement will be collected from clinician attendance sheets in the medical record and medical record review for prescriptions. Medication use will be confirmed with self-report of taking medication.

Time frame:
6 months
Reported as:
Number · participants
Number of Subjects That Initiated Cessation Treatment
participantsLet's Talk About SmokingNational Cancer Institute (NCI) Computerized Education
Number of Subjects That Initiated Cessation Treatment2736
SecondaryNumber of Subjects With Confirmed Abstinence

Biologically confirmed abstinence: we will confirm 7-day point prevalence abstinence at 6 month assessments (self-reported abstinence without any smoking, "not even a puff," for the past 7 days,) with expired carbon monoxide (reading ≤9).

Time frame:
6 months
Reported as:
Number · participants
Number of Subjects With Confirmed Abstinence
participantsLet's Talk About SmokingNational Cancer Institute (NCI) Computerized Education
Number of Subjects With Confirmed Abstinence16
SecondaryNumber of Subjects With a Quit Attempt With 7 or More Days of Self-reported Abstinence
Time frame:
6 months
Reported as:
Count of participants · Participants
Number of Subjects With a Quit Attempt With 7 or More Days of Self-reported Abstinence
ParticipantsBehavioral InterventionEducational Intervention
Number of Subjects With a Quit Attempt With 7 or More Days of Self-reported Abstinence1311

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Behavioral Intervention—1/78 (1.3%)0/78 (0%)
Educational Intervention—0/84 (0%)1/84 (1.2%)
Most frequent serious events
Most frequent serious events
EventBehavioral InterventionEducational Intervention
DeathCardiac disorders1/780/84
Most frequent other events
Most frequent other events
EventBehavioral InterventionEducational Intervention
Suicidal ideationPsychiatric disorders0/781/84

Baseline characteristics

Age, Continuous
Age, Continuous(years)Behavioral InterventionEducational InterventionTotal
Mean47.62 ± 11.2944.32 ± 11.1845.91 ± 11.32
Sex: Female, Male
Sex: Female, Male(Participants)Behavioral InterventionEducational InterventionTotal
Female292554
Male4959108
Region of Enrollment
Region of Enrollment(participants)Behavioral InterventionEducational InterventionTotal
United States7884162
Brief Psychiatric Rating Scale
Brief Psychiatric Rating Scale(units on a scale)Behavioral InterventionEducational InterventionTotal
Mean41.79 ± 11.9540.38 ± 10.3241.06 ± 11.11
Positive and Negative Affect Schedule - Positive
Positive and Negative Affect Schedule - Positive(units on a scale)Behavioral InterventionEducational InterventionTotal
Mean22.36 ± 8.6622.31 ± 8.4822.33 ± 8.54
Positive and Negative Affect Schedule - Negative
Positive and Negative Affect Schedule - Negative(units on a scale)Behavioral InterventionEducational InterventionTotal
Mean12.04 ± 9.0912.06 ± 9.4512.05 ± 9.25
Cognition battery Z Scores
Cognition battery Z Scores(units on a scale)Behavioral InterventionEducational InterventionTotal
Mean-.029 ± 0.68.016 ± 0.70-.006 ± 0.69
Cigarettes per day
Cigarettes per day(cigarettes)Behavioral InterventionEducational InterventionTotal
Mean14.48 ± 9.6214.64 ± 11.314.56 ± 10.49

1 further baseline measures are reported on the registry.

08

Study locations

3 sites
  • Thresholds
    Chicago, Illinois 60613, United States
  • University of Massachusetts
    Worcester, Massachusetts 01605, United States
  • Rutgers-UNDMJ
    New Brunswick, New Jersey 08901, United States
09

References and documents

Publications

  • Brunette MF, Ferron JC, McGurk SR, Williams JM, Harrington A, Devitt T, Xie H. Brief, Web-Based Interventions to Motivate Smokers With Schizophrenia: Randomized Trial. JMIR Ment Health. 2020 Feb 8;7(2):e16524. doi: 10.2196/16524. PubMed 32039811 ↗

Individual participant data

Plan to share: Yes — De-identified research data files will be made available to all researchers in both the public and private sectors for potential statistical analyses or re-analyses in accordance with the NIH data Sharing Policy: http://grants.nih.gov/grants/policy/data sharing. Data will be available 2 years after data collection is completed, or after primary papers have been accepted for publication. Data will only be transferred to other researchers under a signed data sharing agreement. Materials and research data files will be made available, upon request, from the PI. These requests can be made via email (mary.f.brunette@dartmouth.edu).

Supporting information: Study protocol

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02086162
Lead sponsor
Dartmouth-Hitchcock Medical Center
Collaborators
National Cancer Institute (NCI)
Responsible party
Mary F. Brunette, MD (Staff Physician, Dartmouth-Hitchcock Medical Center) — Principal investigator
First posted
Mar 13, 2014
Start date
Apr 2014
Primary completion
Jul 2016
Completion
Jul 2016
Results posted
Oct 12, 2018
Last update
Nov 29, 2018

Study contacts

Mary F. Burnette, MD
principal investigator · Dartmouth-Hitchcock Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion